2 research outputs found
The synthesis of chiral organosul fur and phosphorus compounds /
A general route to optically active organosulfur and phosphorus compounds was investigated. Sulfinimides incorporating camphorimide were synthesized directly from a sulfinyl chloride and N-(trimethylsilyl)camphorimide. The diastereomers were found to be inseparable by crystallization or chromatography, although in one case an optically active sulfinamide was prepared by an asymmetric synthesis.The phosphorus-imide bond was formed by coupling of an asymmetric phosphinous chloride and N-(trimethylsilyl)camphorimide. Addition of sulfur gave N-(phosphinothioyl)camphorimides as separable diastereomers. These were converted into optically active thiophosphoryl compounds which were chiral only at phosphorus. The absolute configurations of the diastereomers were obtained by single-crystal X-ray analysis, through NMR techniques and by conversion into phosphinothioic acids.Displacement of camphorimide was effected with organometallic reagents, alcohols and thiols to give optically active phosphine sulfides, phosphinothionates and phosphinodithioates respectively. Optical yields of the products were dependant on the reagents and reaction conditions used. Mechanistic rationales are presented to account for the stereochemical results
Recommended from our members
Defining the prevalence of inherited DNA damage repair genetic variants (DDRv) in men with prostate cancer (PCa) detected by PSMA PET.
e17010
Background: Approximately 12% of patients (pts) with metastatic PCa (mPCa) identified by conventional imaging harbor DDRv. The increased use of PSMA PET has identified a group of pts with extra-prostatic PCa which is not apparent on conventional imaging and for whom the frequency of germline DDRv testing remains unknown. Methods: A single-institution retrospective analysis of patients with PCa detected by PSMA PET who had also undergone germline genetic testing was undertaken. Data collected included PSA level at time of PSMA PET imaging, stage/Gleason score at diagnosis (dx), rationale for germline testing, castration status, and whether the metastatic disease identified on PSMA PET represented de novo or recurrent mPCa. Germline sequencing results were evaluated for 16 DNA damage repair genes: ATM, ATR, BAP1, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, GEN1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, and RAD51D. The frequency of DDRv was evaluated in groups defined by PSMA imaging results: localized (N0M0), Node-Positive (N+M0), metastatic (M+) PCa. Results: Of 795 PCa pts who underwent germline testing and 2101 PCa pts who underwent PSMA PET imaging, 386 had undergone both, and constitute the study cohort. In the study cohort the distribution of PCa extent identified by PSMA PET was: 81/386 (21.0%) N0M0; 76/386 (19.7%) N+M0; 229/386 (59.3%) M+. There were no statistically significant differences in the prevalence of DDRv with regards to age, Gleason score at dx, PSA at time of imaging, castration status at time of imaging, rationale for germline testing, or if metastatic, whether de novo or recurrent. The distribution of DDRv is shown in the table. There were no statistically significant differences between groups. Conclusions: The overall frequency of pathogenic germline DDRv in PCa pts who had undergone PSMA PET imaging was 4.66%, considerably lower than what has been reported in men with mPCa detected with conventional imaging. The presence or absence of extra-prostatic PCa detected by PSMA PET imaging did not appear to affect the frequency of DDRv. Validation of these findings in other cohorts will be important to guide recommendations for germline genetic testing in the growing group of PCa pts undergoing PSMA PET imaging. [Table: see text